



September 20, 2025

To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL
--	---

Sub: Intimation as per Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') – Development of New Product

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation), and in line with the Company's continuous efforts towards innovation and growth, we are pleased to inform that the company has successfully developed a new products as under:

Sr. No.	Name of the Product	Therapeutic use	Expected launch / Commercialisation
1	Artemether	Anti-Malarial	November, 2025
2	Lumefantrine	Anti-Malarial	November, 2025

This development is in line with our strategy to expand the product portfolio and cater to the evolving needs of our clientele.

The Company will intimate to Stock Exchange for further development in this matter.

You are requested to take the above information on your record.

Thanking You.

Yours Faithfully,

For ANLON HEALTHCARE LIMITED

**PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258**

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in